FDA Drug Recalls

Recalls / Class II

Class IID-0993-2022

Product

EPI-PEN 2-PAK (epinephrine injection, USP), Single-Dose Auto-Injectors 0.3 mg, Rx only, Manufactured for: Mylan Specialty LP., NDC 49502-500-02

Brand name
Epipen
Generic name
Epinephrine
Active ingredient
Epinephrine
Route
Intramuscular
NDCs
49502-500, 49502-501
FDA application
NDA019430
Affected lot / code info
McKesson Medical-Surgical (MMS) is not able to identify the particular lot number received by a particular consignee for the recalled prescription products. Each letter includes the date it was distributed to customers and the dates that impacted product may have been shipped to the customer. The letters clearly explain that consignees should identify product received from MMS between June 1 and September 30, 2021. A consignee should be able to use its own records to determine whether it received an impacted product from MMS during that timeframe and whether it still has any of that product in inventory. The recall notification letter informs consignees that they may contact Sedgwick if they have any questions.

Why it was recalled

cGMP deviations: Temperature abuse

Recalling firm

Firm
Mckesson Medical-Surgical Inc. Corporate Office
Manufacturer
Viatris Specialty LLC
Notification channel
Letter
Type
Voluntary: Firm initiated
Address
9954 Maryland Drive, Deep Run Iii Ste. 4000, Richmond, Virginia 23233

Distribution

Quantity
5 cartons
Distribution pattern
USA nationwide.

Timeline

Recall initiated
2022-04-13
FDA classified
2022-06-09
Posted by FDA
2022-06-15
Terminated
2023-11-30
Status
Terminated

Source: openFDA Drug Enforcement endpoint. Recall record D-0993-2022. The FDA issues recall classifications as health-hazard assessments, not legal findings; for legal claims consult a licensed attorney.

Class II recall: Epipen · FDA Drug Recalls